Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix for Prostate Downsizing Prior to Brachytherapy
NCT01446991Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2012
- Primary completion
- Feb 2017
- Countries
- 1
- Sponsor
- BC Cancer
- Modality
- Peptides, Small Molecules
- Drugs
- degarelix
- Conditions
- prostate cancer (PCa)
01
Overview
Phase 2, open-label trial of degarelix in prostate cancer (PCa) (2 arms), sponsored by BC Cancer. Primary endpoint: Prostate volume reduction at 3 months. Started Apr 2012; status: completed.
02
Design
2 arms- Study design
- Non-randomizedOpen-label
Favorable prostate cancer with pubic arch interference
Men with favorable risk disease requiring downsizing. Degarelix for 2-3 months.
Intermediate risk prostate cancer
Men with intermediate risk disease requiring 6 months androgen ablation. Degarelix for 6 months.
03
Who it enrols
Men with favorable or intermediate risk prostate cancer requiring prostate downsizing or androgen ablation prior to brachytherapy.
04
Endpoints
Primary
Prostate volume reduction
Secondary
Testosterone recovery
Beyond the preview
Go deeper on NCT01446991.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01446991.